How a Korean biotech startup is using AI to move drug discovery from trial-and-error to precision design
A close up of a protein structure model. PHOTO: UNSPLASH
For decades, drug discovery has relied on trial and error, with scientists testing thousands of molecules to find one that works. Galux, a South Korean biotech startup, is changing that by using AI to design proteins from scratch. This method, called “de novo” design, makes it possible to build precise new therapies instead of searching through existing ones.
The company recently announced a US$29 million Series B funding round, bringing its total capital to US$47 million.This significant investment attracted a substantial roster of institutional backers, including the Korea Development Bank (KDB), Yuanta Investment, SL Investment and NCORE Ventures. These firms joined existing investors such as InterVest, DAYLI Partners and PATHWAY Investment, as well as new participants including SneakPeek Investments, Korea Investment & Securities and Mirae Asset Securities.
At the core of the company’s work is a platform called GaluxDesign. Unlike many AI tools that only predict how existing proteins fold, this system uses deep learning and physics to create entirely new therapeutic antibodies. This “from scratch” approach lets the team go after so-called “undruggable” proteins. These are targets that traditional small-molecule drugs can’t reach because they lack clear binding pockets. By designing proteins to fit these complex shapes, Galux aims to unlock treatments that have stayed out of reach for decades. And that’s exactly why investors are paying attention.
The pharmaceutical industry is actively looking for faster and more efficient ways to develop new drugs, and Galux is built for exactly that. The company connects its AI platform directly to its own wet lab, where designs can be tested in real time. Each result feeds straight back into the system, sharpening the next round of models. This continuous loop speeds up discovery and improves precision at every step. It’s also why partners like Celltrion, LG Chem and Boehringer Ingelheim are already working with Galux.
Galux is no longer just trying to make drugs that stick to a target. The company now wants its AI to design medicines that actually work in the body and can be made at scale. In simple terms, a drug has to do more than bind to a disease—it must be stable, safe and strong enough to change how the illness behaves. Galux is moving into tougher targets such as ion channels and GPCRs. These play key roles in heart function and sensory signals. Ultimately, the goal is to show that AI-driven design can turn complex biology into real treatments. And instead of hunting blindly for a solution, the team is building exactly what they need.
Keep Reading
How ECOPEACE uses autonomous robots and data to monitor and maintain urban water bodies.
Updated
January 23, 2026 10:41 AM
A school of fish swimming among debris and waste. PHOTO: UNSPLASH
South Korea–based water technology company ECOPEACE is working on a practical challenge many cities face today: keeping urban water bodies clean as pollution and algae growth become more frequent. Rather than relying on periodic cleanup drives, the company focuses on systems that can monitor and manage water conditions on an ongoing basis.
At the core of ECOPEACE’s work are autonomous water-cleanup robots known as ECOBOT. These machines operate directly on lakes, reservoirs and rivers, removing algae and surface waste while also collecting information about water quality. The idea is to combine cleaning with constant observation so changes in water conditions do not go unnoticed.
Alongside the robots, ECOPEACE uses a filtration and treatment system designed to process polluted water continuously. This system filters out contaminants using fine metal filters and treats the water using electrical processes. It also cleans itself automatically, which allows it to run for long periods without frequent manual maintenance.
The role of AI in this setup is largely about decision-making rather than direct control. Sensors placed across the water body collect data such as pollution levels and water quality indicators. The software then analyses this data to spot early signs of issues like algae growth. Based on these patterns, the system adjusts how the robots and filtration units operate, such as changing treatment intensity or water flow. In simple terms, the technology helps the system respond sooner instead of waiting for visible problems to appear.
ECOPEACE has already deployed these systems across several reservoirs, rivers and urban waterways in South Korea. Those projects have helped refine how the robots, sensors and software work together in real environments rather than controlled test sites.
Building on that experience, the company has begun expanding beyond Korea. It is currently running pilot and proof-of-concept projects in Singapore and the United Arab Emirates. These deployments are testing how the technology performs in dense urban settings where waterways are closely linked to public health, infrastructure and daily city life.
Both regions have invested heavily in smart city initiatives and water management, making them suitable test beds for automated monitoring and cleanup systems. The pilots focus on algae control, surface cleaning and real-time tracking of water quality rather than large-scale rollout.
As cities continue to grow and climate-related pressures on water systems increase, managing waterways is becoming less about occasional intervention and more about continuous oversight. ECOPEACE’s approach reflects that shift by using automation and data to address problems early and reduce the need for reactive cleanup later.